ROBERT DEAN GLAZER, M.D.
Osteopathic Medicine at Wyckoff Ave, Piscataway, NJ
License number
New Jersey 25MA03947400
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
109 Wyckoff Ave, Piscataway, NJ 08854
Phone
(732) 563-4194
Professional information
Dr. Robert D Glazer, Piscataway NJ - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
109 Wyckoff Ave, Piscataway 08854
(732) 563-4194 (Phone), (732) 563-4194 (Fax)
(732) 563-4194 (Phone), (732) 563-4194 (Fax)
Languages:
English
Pharmaceutical Composition Comprising Valsartan
US Patent:
2009010, Apr 23, 2009
Filed:
Dec 22, 2008
Appl. No.:
12/341669
Inventors:
Jay Norman Cohn - Minneapolis MN, US
Robert Dean Glazer - Piscataway NJ, US
Robert Latini - Milan, IT
Aldo Pietro Maggioni - Florence, IT
Gianni Tognoni - Milan, IT
Robert Dean Glazer - Piscataway NJ, US
Robert Latini - Milan, IT
Aldo Pietro Maggioni - Florence, IT
Gianni Tognoni - Milan, IT
International Classification:
A61K 31/41, A61P 9/00
US Classification:
514381
Abstract:
The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in combination with another therapeutic agent, optionally in the presence of a pharmaceutically acceptable carrier.
Pharmaceutical Composition Comprising Valsartan
US Patent:
2007005, Mar 8, 2007
Filed:
May 14, 2004
Appl. No.:
10/556260
Inventors:
Jay Cohn - MINNEAPOLIS MN, US
Robert Glazer - Piscataway NJ, US
Robert Latini - Milan, IT
Aldo Maggioni - Florence, IT
Gianni Tognoni - Milan, IT
Robert Glazer - Piscataway NJ, US
Robert Latini - Milan, IT
Aldo Maggioni - Florence, IT
Gianni Tognoni - Milan, IT
International Classification:
A61K 31/41
US Classification:
514381000
Abstract:
The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in combination with another therapeutic agent, optionally in the presence of a pharmaceutically acceptable carrier.